eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


1/2005
vol. 4
 
Share:
Share:
abstract:

Vaginal applying of 17β-estradiol in the treatment of urogynecological complaints – own experiences

Grzegorz Surkont
,
Jacek Suzin
,
Edyta Wlaźlak
,
Tomasz Paszkowski
,
Tomasz Rechberger

Prz Menopauz 2005; 1: 37–43
Online publish date: 2005/02/15
View full text Get citation
 
92 women (aged 45-77 yrs) with urogenital complaints (atrophic vaginitis, dyspareunia and/or urinary incontinence) were recruited to take part in this prospective study. We analyzed the tolerabilty profile, compliance, patient’s satisfaction and the efficacy variables during the three months of treatment with vaginal tablets containing 25 µg of 17β-estradiol (Vagifem, Novo Nordisk). Clinical evaluation and the questionnaire study were performed at the baseline and after 6 and 12 weeks of the treatment. Eighty three women (90.2%) who fulfilled the last visit served as a study population. Treatment with vaginal tablets containing 25 µg of 17β-estradiol appeared to be effective in reducing atrophic vaginitis symptoms in postmenopausal women. A significant reduction of subjective symptoms of urinary incontinence was observed by 21.7% of patients. Vaginal tablets with ultra-low dose of estradiol have good tolerability profile and are associated with high degree of compliance.
keywords:

vaginal estrogen therapy, atrophic vaginitis, dyspareunia, urinary incontinence, menopause

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.